The Complaint alleges that throughout the Class Period, Defendants made false and misleading statements to investors and/or failed to disclose that: (1) the clinical hold placed on the Phase 3 trial of Aldoxorubicin for STS would inhibit the necessary follow-up for patients in the study; (2) close to half of the patients would be excluded from the progression free survival evaluation; (3) CytRx would probably need a second analysis; (4) the trial's results could be materially affected and/or approval of Aldoxorubicin for STS could be delayed; and (5) consequently, CytRx's public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action please visit the firm's site: http://www.bgandg.com/#!cytr/lvnfh or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in CytRx you have until September 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert---bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-against-cytrx-corporation-cytr-and-lead-plaintiff-deadline-september-23-2016-300307825.html
SOURCE Bronstein, Gewirtz & Grossman, LLC